IMMUNOHISTOCHEMICAL DETECTION OF THE P53 GENE-PRODUCT IN GASTRIC-CANCER PATIENTS - ABERRANT EXPRESSION BUT NO PROGNOSTIC-SIGNIFICANCE
- Authors:
- Published online on: November 1, 1994 https://doi.org/10.3892/or.1.6.1263
- Pages: 1263-1268
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The aim of the present study was to examine whether immunohistochemical p53 expression could be identified as an independent predictor for disease recurrence and survival and to assess any relation to tumour type, metastatic potential and response to different therapeutic regimens. We examined gastric carcinomas from 125 patients using a mouse monoclonal antibody (DO7). Seventy two of the tumours showed positive nuclear staining. No special relation was observed either according to tumour type, grade or stage classification of the tumours nor to the lymph node status. Survival analysis showed no significant advantage of the p53 negative patients. Expression of p53 in our series did not prove to be a valuable prognostic marker for survival nor did it correlate with other standard prognostic markers.
